CO5560566A2 - Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson - Google Patents

Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson

Info

Publication number
CO5560566A2
CO5560566A2 CO04023011A CO04023011A CO5560566A2 CO 5560566 A2 CO5560566 A2 CO 5560566A2 CO 04023011 A CO04023011 A CO 04023011A CO 04023011 A CO04023011 A CO 04023011A CO 5560566 A2 CO5560566 A2 CO 5560566A2
Authority
CO
Colombia
Prior art keywords
alkyl
alkoxy
dialkylamino
hydroxy
alkylamino
Prior art date
Application number
CO04023011A
Other languages
English (en)
Spanish (es)
Inventor
Samuel Hintermann
Bastian Hengerer
Krosigk Ulrike Von
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5560566A2 publication Critical patent/CO5560566A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CO04023011A 2001-08-15 2004-03-12 Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson CO5560566A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0119911.6A GB0119911D0 (en) 2001-08-15 2001-08-15 Organic Compounds

Publications (1)

Publication Number Publication Date
CO5560566A2 true CO5560566A2 (es) 2005-09-30

Family

ID=9920454

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04023011A CO5560566A2 (es) 2001-08-15 2004-03-12 Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson

Country Status (24)

Country Link
US (1) US7087756B2 (enExample)
EP (1) EP1418912B1 (enExample)
JP (1) JP2005501847A (enExample)
KR (1) KR20040029429A (enExample)
CN (1) CN100384418C (enExample)
AR (1) AR036351A1 (enExample)
AT (1) ATE355059T1 (enExample)
BR (1) BR0211903A (enExample)
CA (1) CA2454762A1 (enExample)
CO (1) CO5560566A2 (enExample)
DE (1) DE60218484T2 (enExample)
EC (1) ECSP044971A (enExample)
ES (1) ES2282467T3 (enExample)
GB (1) GB0119911D0 (enExample)
HU (1) HUP0401325A3 (enExample)
IL (1) IL160018A0 (enExample)
MX (1) MXPA04001419A (enExample)
NO (1) NO20040659D0 (enExample)
PE (1) PE20030356A1 (enExample)
PL (1) PL366848A1 (enExample)
PT (1) PT1418912E (enExample)
RU (1) RU2004107847A (enExample)
WO (1) WO2003015780A2 (enExample)
ZA (1) ZA200400525B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102807A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof
CA2564429A1 (en) * 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators
WO2007098047A2 (en) * 2006-02-16 2007-08-30 The Mclean Hospital Corporation Methods and compositions for the treatment of parkinson's disease
EP2051977A2 (en) 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
FR2933609B1 (fr) * 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
US8173670B2 (en) * 2009-01-13 2012-05-08 Van Andel Research Institute Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
FR2950053B1 (fr) 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR2955110A1 (fr) 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
DE102011085038A1 (de) 2011-10-21 2013-04-25 Tesa Se Verfahren zur Kapselung einer elektronischen Anordnung
HK1222565A1 (zh) 2013-09-25 2017-07-07 范安德尔研究所 高效糖皮質激素
KR20170033630A (ko) 2015-09-17 2017-03-27 (주)다올 도로용 경계블럭
US10954265B2 (en) 2016-10-14 2021-03-23 Van Andel Research Institute Structures and mechanism for the design of highly potent glucocorticoids

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7602542L (sv) 1975-03-14 1976-09-15 Sandoz Ag 3-(alfa-iminobensyl)-4-hydroxi-2(lh)-pyridoner
US4064251A (en) * 1976-06-25 1977-12-20 Sandoz, Inc. Substituted hydroxy pyridones
US4049813A (en) 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
DE2801190A1 (de) * 1977-01-19 1978-07-20 Sandoz Ag 3-(alpha-iminobenzyl)-4-hydroxy-2(1h)- pyridon-derivat
US4238616A (en) 1977-01-19 1980-12-09 Sandoz, Inc. 3-(Substituted)phenyl-5-(β-hydroxyphenethyl)-N-(alkyl)-isoxazole-4-carboxamides
US4113727A (en) * 1977-04-26 1978-09-12 Sandoz, Inc. Process for the preparation of substituted isoxazolo[4,5-c]pyridin-4-(5H)-ones
WO2002102807A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof

Also Published As

Publication number Publication date
NO20040659L (no) 2004-02-13
BR0211903A (pt) 2004-09-21
KR20040029429A (ko) 2004-04-06
HUP0401325A2 (hu) 2004-10-28
MXPA04001419A (es) 2004-05-27
CN100384418C (zh) 2008-04-30
ECSP044971A (es) 2004-03-23
US7087756B2 (en) 2006-08-08
DE60218484D1 (de) 2007-04-12
NO20040659D0 (no) 2004-02-13
PT1418912E (pt) 2007-05-31
PL366848A1 (en) 2005-02-07
CN1635889A (zh) 2005-07-06
JP2005501847A (ja) 2005-01-20
WO2003015780A8 (en) 2004-05-21
DE60218484T2 (de) 2007-11-15
ES2282467T3 (es) 2007-10-16
EP1418912B1 (en) 2007-02-28
CA2454762A1 (en) 2003-02-27
PE20030356A1 (es) 2003-05-14
ZA200400525B (en) 2005-04-01
US20040248893A1 (en) 2004-12-09
IL160018A0 (en) 2004-06-20
WO2003015780A3 (en) 2003-11-13
RU2004107847A (ru) 2005-05-10
HUP0401325A3 (en) 2005-09-28
ATE355059T1 (de) 2006-03-15
EP1418912A2 (en) 2004-05-19
GB0119911D0 (en) 2001-10-10
WO2003015780A2 (en) 2003-02-27
AR036351A1 (es) 2004-09-01

Similar Documents

Publication Publication Date Title
SE0203754D0 (sv) New compounds
PE20061164A1 (es) Piperazin-piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3
ATE211466T1 (de) Depsipeptide, herstellung und anwendung
BRPI0413232A (pt) novos compostos tendo atividade inibitória contra os trasnportadores dependentes de sódio
PE20061305A1 (es) Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas
ATE284860T1 (de) Neue verwendung von phenylheteroalkylamin- derivaten
DE60237425D1 (de) PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
BR0313407A (pt) Novo uso de derivados de benzotiazol
CA2279620A1 (en) 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (d4)
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
DE69009646D1 (de) Substituierte Harnstoffverbindungen, ihre Herstellung und Verwendung.
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
NZ514542A (en) Vasopressin antagonists for the treatment of pulmonary hypertension
WO2004017977A3 (en) 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
AR035451A1 (es) Derivados de beta-carbolina, su uso para la fabricacion de un medicamento para el tratamiento de la depresion, ansiedad y desordenes bipolares, una composicion farmaceutica y una combinacion.
RU2004117543A (ru) Амиды антраниловой кислоты и их применение в качестве ингибиторов тирозинкиназного рецептора фактора роста сосудистого эндотелия (vegf)
AR036351A1 (es) Isoxazolopiridinonas, el uso de las mismas para la fabricacion de un medicamento, composiciones y combinaciones farmaceuticas
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
TW200505446A (en) Inhibitor of cox
JP2005501847A5 (enExample)
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
PT1463504E (pt) Composicoes compreendendo epotilonas e sua utilizacao para o tratamento de sindroma carcinoide
WO2002074777A3 (en) Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
NO961077D0 (no) Substituerte benzoltienylpiperaziner, deres anvendelse som medikamenter og fremgangsmåter for fremstilling
SG148023A1 (en) New benzothiazine and benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA Application withdrawn